These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 31659111)

  • 1. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
    Torralvo J; Friedlaender A; Achard V; Addeo A
    Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.
    Liu J; Gao J
    Eur J Cancer Prev; 2023 Nov; 32(6):590-599. PubMed ID: 37038985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
    Barsouk A; Friedes C; Iocolano M; Doucette A; Cohen RB; Robinson KW; D'Avella CA; Marmarelis ME; Kosteva JA; Singh AP; Ciunci CA; Levin WP; Cengel KA; Bradley JD; Feigenberg SJ; Sun L; Aggarwal C; Langer CJ; Yegya-Raman N
    Clin Lung Cancer; 2024 May; 25(3):e161-e171. PubMed ID: 38195320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
    Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
    Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
    Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M
    Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
    Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 19. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
    Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.
    Veccia A; Dipasquale M; Kinspergher S; Monteverdi S; Girlando S; Barbareschi M; Caffo O
    Target Oncol; 2023 Jan; 18(1):129-138. PubMed ID: 36482151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.